MarketCap
Facebook
X
Telegram
VYNE Therapeutics Balance Sheet 2026-2011 | VYNE
Brief overview of VYNE Therapeutics 's balance sheet structure
Balance sheet changes are traced across five available annual reports between 2021 and 2025.
Assets fell from $67 million to $30.2 million. This may reflect either deliberate optimization or a reduction in business scale.
Liability growth of -87% trailed asset growth of -55%. The funding structure became more resilient.
Internal capital represents 92.1% of the balance sheet, previously 72.5%. This is a strong capital position.
Cash equals 79.7% of the balance sheet, compared with 63% five periods ago. This is the readily available cushion.
The balance sheet includes a negative accumulated result of -$757.7 million. It should be assessed alongside historical profits and capital distributions.
Balance sheet takeaway
VYNE Therapeutics 's balance sheet sends more positive than negative signals, but liabilities should not begin outpacing the capital base.
Annual Balance Sheet VYNE Therapeutics
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | -30.4 M | - | - | -22.8 M | -30.8 M | -49.5 M | -10.2 M | -4.03 M | -43.8 M | - | - | - | - |
Long Term Debt |
- | - | - | 99 K | - | - | 33.2 M | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
- | - | 99 K | 115 K | - | 349 K | 757 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 1.41 M | - | - | 34.8 M | - | 7 K | 116 M | 67.6 M | 59.1 M | - | - | - | - |
Total Current Liabilities |
1.24 M | 2.4 M | 14.8 M | 7.54 M | 9.34 M | - | 21.5 M | 10.7 M | 9.54 M | 7.82 M | - | - | - | - | - | - |
Total Liabilities |
1.24 M | 2.4 M | 14.8 M | 8.95 M | 9.34 M | 18.4 M | 56.2 M | 10.7 M | 9.55 M | 124 M | 71.5 M | 59.8 M | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | 1.8 M | 1.8 M | - | - | - | - | - |
Retained Earnings |
-761 M | -758 M | -731 M | -691 M | -663 M | -640 M | -566 M | - | -111 M | -59.2 M | -30.1 M | -16 M | - | - | - | - |
Total Assets |
25.9 M | 30.2 M | 66.9 M | 97.7 M | 40.8 M | 67 M | 93.7 M | 79.2 M | 140 M | 66.9 M | 42.1 M | 43.9 M | - | - | - | - |
Cash and Cash Equivalents |
24.6 M | 24 M | 19.9 M | 30.6 M | 30.9 M | 42.2 M | 57.6 M | 30.8 M | 49.5 M | 10.2 M | 4.03 M | 43.8 M | - | - | - | - |
Book Value |
24.6 M | 27.8 M | 52.1 M | 88.7 M | 31.4 M | 48.6 M | 37.5 M | 68.5 M | 130 M | -57 M | -29.4 M | -16 M | - | - | - | - |
Total Shareholders Equity |
24.6 M | 27.8 M | 52.1 M | 88.7 M | 31.2 M | 48.6 M | 37.5 M | 17.6 M | 130 M | -57 M | -29.4 M | -16 M | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet VYNE Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | - | - | 99 K | - | - | - | - | - | - | - | - | - | - | 33.3 M | 33.2 M | 33.2 M | 33.2 M | 33.2 M | 32.7 M | 32.7 M | 32.7 M | 32.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | 25 K | - | 1.41 M | - | - | - | - | - | - | - | - | - | - | - | 34.5 M | 35 M | 35.1 M | 34.4 M | 34.3 M | 34.3 M | 34.3 M | 34.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
2.4 M | 1.24 M | 14.8 M | 5.84 M | 12.3 M | 14.8 M | 12.7 M | 11.8 M | - | 8.95 M | 7.76 M | 7.69 M | 8.83 M | 9.34 M | 6.84 M | 6.84 M | 8.59 M | 18.4 M | 22.4 M | 59.1 M | 56.3 M | 56.2 M | 56.2 M | 56.2 M | 56.2 M | 63.6 M | 63.6 M | 63.6 M | 63.6 M | 9.55 M | 9.55 M | 9.55 M | 9.55 M | 14.6 M | 14.6 M | 14.6 M | 14.6 M | 12.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-758 M | -761 M | -731 M | -746 M | -740 M | -731 M | -719 M | -707 M | - | -691 M | -685 M | -679 M | -669 M | -663 M | -653 M | -643 M | -635 M | -640 M | -628 M | -607 M | -587 M | -566 M | -566 M | -566 M | -566 M | -311 M | -311 M | -311 M | -311 M | -111 M | -111 M | -111 M | -111 M | -59.2 M | -59.2 M | -59.2 M | -59.2 M | -30.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
30.2 M | 25.9 M | 66.9 M | 44.7 M | 56.4 M | 66.9 M | 76.2 M | 86.6 M | - | 97.7 M | 19.3 M | 25 M | 35.3 M | 40.8 M | 46.9 M | 55.2 M | 64.3 M | 67 M | 81.3 M | 134 M | 149 M | 93.7 M | 93.7 M | 93.7 M | 93.7 M | 81.2 M | 81.2 M | 81.2 M | 81.2 M | 140 M | 140 M | 140 M | 140 M | 66.9 M | 66.9 M | 66.9 M | 66.9 M | 42.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
19.9 M | 24.6 M | 30.7 M | 22 M | 28.2 M | 19.9 M | 16.3 M | 29.6 M | 19.1 M | 30.6 M | 15.4 M | 20.6 M | 30.2 M | 30.9 M | 35.5 M | 42.8 M | 50.5 M | 42.2 M | 52.3 M | 103 M | 119 M | 57.6 M | 57.6 M | 57.6 M | 57.6 M | 43.8 M | 43.8 M | 43.8 M | 43.8 M | 27.9 M | 49.5 M | 49.5 M | 49.5 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 4.03 M | - | - | - | 43.8 M | - | - | - | 273 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
27.8 M | 24.6 M | 52.1 M | 38.9 M | 44.1 M | 52.1 M | 63.5 M | 74.9 M | - | 88.7 M | 11.5 M | 17.3 M | 26.4 M | 31.4 M | 40.1 M | 48.4 M | 55.7 M | 48.6 M | 58.9 M | 74.9 M | 92.9 M | 37.5 M | 37.5 M | 37.5 M | 37.5 M | 17.6 M | 17.6 M | 17.6 M | 17.6 M | 130 M | 130 M | 130 M | 130 M | 52.3 M | 52.3 M | 52.3 M | 52.3 M | 29.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
52.1 M | 24.6 M | 88.7 M | 38.9 M | 44.1 M | 52.1 M | 63.5 M | 74.9 M | 83.4 M | 88.7 M | 11.5 M | 17.3 M | 26.4 M | 31.2 M | 40.1 M | 48.4 M | 55.7 M | 48.6 M | 58.9 M | 74.9 M | 92.9 M | 37.5 M | 37.5 M | 37.5 M | 37.5 M | 17.6 M | 17.6 M | 17.6 M | 17.6 M | 92.2 M | 130 M | 130 M | 130 M | 68.6 M | -57 M | -57 M | -57 M | -29.4 M | - | - | - | -16 M | - | - | - | -11.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of VYNE Therapeutics , providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.